Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
Completed
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 1/Phase 2
2001-08-01
Treatment of HIV-infected patients involves combining drugs from different classes of
anti-HIV drugs. One preferred regimen for adults is 2 nucleoside reverse transcriptase
inhibitors (NRTIs) and 1 protease inhibitor (PI). For children, this regimen may be too
complicated or the drugs may be too difficult to take by mouth. The purpose of this study was
to determine the long-term safety and effectiveness of daily didanosine (ddI), efavirenz
(EFV), and emtricitabine (FTC) in pediatric patients who had taken few or no anti-HIV drugs.
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1/Phase 2
2001-08-01
Treatment of HIV-infected patients involves combining drugs from different classes of
anti-HIV drugs. One preferred regimen for adults is 2 nucleoside reverse transcriptase
inhibitors (NRTIs) and 1 protease inhibitor (PI). For children, this regimen may be too
complicated or the drugs may be too difficult to take by mouth. The purpose of this study was
to determine the long-term safety and effectiveness of daily didanosine (ddI), efavirenz
(EFV), and emtricitabine (FTC) in pediatric patients who had taken few or no anti-HIV drugs.
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
Completed
AIDS Clinical Trials Group
N/A
2003-10-01
HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy
the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called
a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced
treatment regimen to decrease the number of resting CD4 cells that become infected with HIV.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
